Wholomics has appointed a clinical-facing specialist to lead hospital onboarding and site activation activities across the United States.
The role will support a prospective, multi-centre clinical validation study focused on evaluating HER2 detection performance against current standard-of-care diagnostics. Working closely with hospital systems and clinical sites, the appointment is designed to accelerate study readiness, improve coordination across participating centres, and support high-quality evidence generation.
As diagnostic and precision oncology platforms move towards broader clinical adoption, the ability to operationalise studies across real-world healthcare environments is becoming increasingly important. Effective site activation and clinical engagement are critical to generating robust comparative data and building confidence among providers and healthcare networks.
Wenham Carter supported the search, identifying a candidate with experience operating at the intersection of clinical operations, hospital engagement, and diagnostic implementation. The appointment strengthens Wholomics’ ability to execute complex validation programmes at scale and lays the groundwork for future clinical adoption in the U.S. market.
